FIELD: medicine.
SUBSTANCE: invention relates to a crystalline polymorphic form of ((7S,13R)-11-fluoro-7,13-dimethyl-6,7,13,14-tetrahydro-1,15-ettenpyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one in the form of a free base, having a powder radiograph containing peaks at diffraction angles (2θ) 9.4±0.1, 16.1±0.1, 16.5±0.1, 18.8±0.1, 21.2±0.1, 22.8±0.1 and 27.4±0.1. The invention also relates to a pharmaceutical composition having properties of an inhibitor of tyrosine kinase receptors ALK, ROS1, TRK, JAK2, SRC and/or FAK, based on the specified compound.
EFFECT: new crystalline form of ((7S,13R)-11-fluoro-7,13-dimethyl-6,7,13,14-tetrahydro-1,15-ettenpyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one and pharmaceutical composition based on it are obtained, which can be used in medicine for the treatment of diseases, such as cancer.
9 cl, 2 dwg, 2 tbl, 29 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR AMINO ACID COMPOUNDS OBTAINING | 2013 |
|
RU2643146C2 |
| METHOD FOR PRODUCTION OF DEGARELIX AND INTERMEDIATE COMPOUNDS THEREOF | 2011 |
|
RU2602042C2 |
| LINEAR LIQUID PATHWAYS FOR WNT HEXAPEPTIDES | 2019 |
|
RU2801268C2 |
| HISTONE DEACETYLASE INHIBITORS | 2016 |
|
RU2720678C2 |
| DERIVATIVES OF QUINOLINE-PYRROLIDINE-2-ONE AND APPLICATION THEREOF | 2019 |
|
RU2771314C1 |
| METHOD OF PRODUCING NITROGEN MUSTARD DERIVATIVES | 2016 |
|
RU2715233C2 |
| SULFOXONIUM YLIDE DERIVATIVES AS PROBES FOR CYSTEINE PROTEASE | 2019 |
|
RU2815018C2 |
| DRUG DELIVERY SYSTEMS BASED ON MAYTANSINOID | 2018 |
|
RU2783076C2 |
| N-METHYLHOMOCYSTEINES, METHODS FOR PRODUCTION AND USES THEREOF | 2002 |
|
RU2305678C2 |
| FUNCTIONALISED DERIVATIVES OF MORPHOLINYLANTHRACYCLINE | 2015 |
|
RU2715902C2 |
